A systematic literature review of clinical evidence and treatment burden in newly diagnosed high‐risk pediatric patients with classical Hodgkin lymphoma

Abstract

AbstractThis systematic literature review evaluated frontline treatment burden in pediatric and adolescent/young adult (AYA) patients with high‐risk classical Hodgkin lymphoma (cHL) among studies originating from the United States. Data were extracted from 32 publications (screened: total, n = 3115; full‐text, n = 98) representing 12 studies (randomized controlled trials [RCTs], n = 2; non‐comparative, non‐randomized, n = 7; observational, n = 3). High‐risk disease definitions varied across studies. Five‐year event‐free survival (EFS)/progression‐free survival (PFS) was 86%–100% and 79%–94%, and complete response rates were 35%–100% and 5%–64% for brentuximab vedotin (BV)‐containing and chemotherapy‐alone regimens, respectively. In identified RCTs, BV‐containing compared with chemotherapy‐alone regimens demonstrated significantly longer 3‐year EFS/5‐year PFS. Hematological and peripheral neuropathy were the most commonly reported adverse events of interest, although safety data were inconsistently reported. Few studies evaluated humanistic and no studies evaluated economic burden. Results from studies with the highest quality of evidence indicate an EFS/PFS benefit for frontline BV‐containing versus chemotherapy‐alone regimens for pediatric/AYA patients with high‐risk cHL.